Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Xếp hạng trong cổ phiếu #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Giá cổ phiếu
$0.0568
Đồng bộ lần cuối: 2026-08-13
Vốn hóa thị trường
$661.36K
Thay đổi (1 ngày)
11.37%
Thay đổi (1 năm)
-5.33%
Quốc gia
US
Giao dịch Hepion Pharmaceuticals, Inc. (HEPA)

Danh mục

Lịch sử giá cổ phiếu của Hepion Pharmaceuticals, Inc. (HEPA)
Giá đóng cửa cao nhất: $0.05 vào 2026-08-01

Giá đóng cửa thấp nhất: $815.99K vào 2014-02-01
Lịch sử giá cổ phiếu của Hepion Pharmaceuticals, Inc. từ 2014 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) -13.53%
2025 -99.75%
2024 -83.90%
2023 -47.81%
2022 -72.98%
2021 -35.82%
2020 -64.66%
2019 -80.01%
2018 -87.43%
2017 -77.91%
2016 -3.97%
2015 1.80%
2014 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
$517.18 32.51%
US
$857.76 31.47%
NL
$728.05 6.60%
CH
$1.07K -6.40%
KR
$254.79 12.56%
BE